A new publication involving lanreotide was indexed on October 1, 2026. The paper, titled "Lanreotide, a Somatostatin Analogue, in Advanced Merkel Cell Carcinoma: A Prospective Single-Arm Phase II Study," appears in the journal Cancer Medicine.
The publication describes a prospective single-arm phase II study examining lanreotide, a somatostatin analogue, in patients with advanced Merkel cell carcinoma. The title identifies the study design as single-arm and phase II in nature.
No specific findings, outcomes, or efficacy data from the study are included in this report. This brief reflects only the existence and bibliographic details of the publication as listed.
Lanreotide is an approved somatostatin analogue. Readers interested in its general pharmacology and approved uses can consult the compound overview for additional context.